Abstract 2698
Background
Triple negative breast cancers are a heterogeneous group of breast cancer candidate to adjuvant chemotherapy in a large majority of cases. However, literature data indicate that the diagnosis of special types of breast cancer might be associated with a different outcome if compared with invasive ductal carcinoma with similar biological features and stages. Selected triple negative apocrine breast cancer can have an extremely good prognosis.
Methods
Among the 210 women with first primary invasive apocrine non metastatic breast cancer operated between January 1998 and December 2016 at European Institute Oncology, Milan, we identified 24 patients with pT1-pT2, node-negative, triple negative subtype and Ki-67 ≤20% who did not receive adjuvant chemotherapy. We compared the outcome of this cohort with a similar group of 48 patients with ductal tumors who received adjuvant chemotherapy, matched by pathological stage and biological features (matching ratio 1:2).
Results
The median age was 63 and 50 years in the apocrine and ductal group, respectively. The mean value of Ki-67 expression was 12% in the apocrine group and 14% in the ductal group. 83% of apocrine tumors had size less than 2 cm, compared with 71% of ductal tumors. After a median follow-up of 6.6 years no patients in the apocrine group experienced a breast cancer related event compared with 12 events (including 5 loco-regional recurrences, 3 distant recurrences e 4 contralateral tumors) in the ductal carcinoma group (Gray test p-value=0.015).
Conclusions
The outcome of selected apocrine triple negative breast cancer patients is excellent and possibly deserves a treatment de-escalation. Multicenter projects focusing on the possibility to avoid adjuvant chemotherapy in selected subtypes of triple negative breast cancers with favorable outcome are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
G. Cancello: Honoraria (self): Pierre Fabre. E. Montagna: Honoraria (self): Pierre fabre; Honoraria (self): gentili. E. Munzone: Honoraria (institution), Advisory / Consultancy: Pierre Fabre; Honoraria (institution), Advisory / Consultancy: Genomic Health. S. Dellapasqua: Travel / Accommodation / Expenses: Roche. M.A. Colleoni: Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Pfizer; Advisory / Consultancy: OBI Pharma; Advisory / Consultancy: Puma Biotechnology; Advisory / Consultancy: Celldex; Advisory / Consultancy: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
3191 - The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) and those with BCLC Stage B hepatocellular carcinoma - A nationwide multicenter study in Japan-
Presenter: Azusa Sakamoto
Session: Poster Display session 2
Resources:
Abstract
1529 - Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase 3 studies (REACH, REACH-2)
Presenter: Andrew Zhu
Session: Poster Display session 2
Resources:
Abstract
2767 - Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study
Presenter: Nicholas Freemantle
Session: Poster Display session 2
Resources:
Abstract
2150 - Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial
Presenter: Jordi Bruix
Session: Poster Display session 2
Resources:
Abstract
3437 - Phase I/II trial of NBTXR3 activated by SBRT in patients with hepatocellular carcinoma or liver metastasis
Presenter: Marc Pracht
Session: Poster Display session 2
Resources:
Abstract
1758 - Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase 3 trials (REACH and REACH-2)
Presenter: Masatoshi Kudo
Session: Poster Display session 2
Resources:
Abstract
1192 - Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure–response analysis
Presenter: Josep Llovet
Session: Poster Display session 2
Resources:
Abstract
1600 - Outcomes of Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab: The Mount Sinai Hospital Experience.
Presenter: Sirish Dharmapuri
Session: Poster Display session 2
Resources:
Abstract
2364 - Pembrolizumab vs Chemotherapy in Patients With Advanced/Metastatic Adenocarcinoma (AC) or Squamous Cell Carcinoma (SCC) of the Esophagus as Second-Line Therapy: Analysis of the Chinese Subgroup in KEYNOTE-181
Presenter: Jia Chen
Session: Poster Display session 2
Resources:
Abstract
1933 - A national comparative effectiveness study to assess definitive chemoradiation regimens in proximal oesophageal squamous cell cancer
Presenter: Judith de Vos-Geelen
Session: Poster Display session 2
Resources:
Abstract